- Home
- BLRX vs NRXS Comparison
BLRX vs NRXS Comparison
Compare BLRX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- NRXS
- Stock Information
- Founded
- BLRX 2003
- NRXS 2011
- Country
- BLRX Israel
- NRXS United States
- Employees
- BLRX N/A
- NRXS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- BLRX Health Care
- NRXS
- Exchange
- BLRX Nasdaq
- NRXS Nasdaq
- Market Cap
- BLRX 12.1M
- NRXS 13.0M
- IPO Year
- BLRX 2011
- NRXS 2023
- Fundamental
- Price
- BLRX $3.09
- NRXS $2.22
- Analyst Decision
- BLRX Buy
- NRXS
- Analyst Count
- BLRX 2
- NRXS 0
- Target Price
- BLRX $26.00
- NRXS N/A
- AVG Volume (30 Days)
- BLRX 17.4K
- NRXS 29.8K
- Earning Date
- BLRX 05-27-2025
- NRXS 05-12-2025
- Dividend Yield
- BLRX N/A
- NRXS N/A
- EPS Growth
- BLRX N/A
- NRXS N/A
- EPS
- BLRX N/A
- NRXS N/A
- Revenue
- BLRX $28,940,000.00
- NRXS $2,934,945.00
- Revenue This Year
- BLRX N/A
- NRXS $138,883.78
- Revenue Next Year
- BLRX N/A
- NRXS $118.59
- P/E Ratio
- BLRX N/A
- NRXS N/A
- Revenue Growth
- BLRX 502.92
- NRXS 27.52
- 52 Week Low
- BLRX $2.30
- NRXS $1.33
- 52 Week High
- BLRX $35.60
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- BLRX 44.89
- NRXS 49.81
- Support Level
- BLRX $3.01
- NRXS $1.94
- Resistance Level
- BLRX $3.25
- NRXS $2.42
- Average True Range (ATR)
- BLRX 0.16
- NRXS 0.26
- MACD
- BLRX -0.02
- NRXS 0.00
- Stochastic Oscillator
- BLRX 0.13
- NRXS 40.99
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).